Puma Biotechnology, Inc. (PBYI)
| Market Cap | 182.20M |
| Revenue (ttm) | 229.13M |
| Net Income (ttm) | 3.72M |
| Shares Out | 47.57M |
| EPS (ttm) | 0.07 |
| PE Ratio | 58.57 |
| Forward PE | 5.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 101,811 |
| Open | 4.28 |
| Previous Close | 4.10 |
| Day's Range | 4.03 - 4.28 |
| 52-Week Range | 2.13 - 5.16 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+98.76%) |
| Earnings Date | Nov 2, 2023 |
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PBYI stock is "Strong Buy" and the 12-month stock price forecast is $8.0.
News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 1, 2023, the Compensation Committee of Puma's Board of Directors approved...
Puma Biotechnology Reports Third Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its Q3-2023 earnings release on Nov. 2, 2023, and hosted a conference call to discuss the results of the quarter.
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Nov. 2, 2023, following the release of its 3Q-2023 results.
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported findings from a Phase I/II study of Alisertib and pembrolizumab for Rb-Deficient HNSCC at the 2023 AACR-NCI-EORTC meeting.
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--The FDA has granted Orphan Drug Designation to Puma Biotechnology's drug candidate alisertib for the treatment of small cell lung cancer.
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO of Puma Biotechnology, will present a corporate update at the H.C. Wainwright Global Investment Conference beginning on 9/11/23.
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma has been notified by the FDA that its IND has been reviewed, and Puma can proceed with clinical development of alisertib monotherapy for SCLC.
Puma Biotechnology Reports Second Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 2Q'23 earnings release on Aug. 3 and hosted a call at 4:30 pm ET to discuss results.
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue operating results for 2Q-2023 on Aug. 3 and follow with a conference call at 1:30 pm PT.
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Biomarker findings from a P II study of alisertib+paclitaxel v. paclitaxel alone in met. HR+ and triple neg breast cancer were presented at ASCO 2023.
Puma Biotechnology Reports First Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--On May 4, Puma Biotechnology reported its earnings results for the quarter ended March 31, 2023.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its financial results for the first quarter of 2023 after market close, followed by a conference call, on May 4, 2023.
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
LOS ANGELES--(BUSINESS WIRE)--Results of Puma's Phase II TBCRC041 trial of alisertib in patients with endocrine-resistant advanced breast cancer published online in JAMA Oncology.
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
LOS ANGELES--(BUSINESS WIRE)--On March 2, 2023, Puma Biotechnology issued its financial results for the fourth quarter and full year ended Dec. 31, 2022.
Puma Biotechnology to Participate in a Panel Discussion at Cowen's 43rd Annual Health Care Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, w...
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 2, 2023, following the...
Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in On...
Puma Biotechnology to Present at B. Riley Securities' 3rd Annual Oncology Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma,...
Puma Biotechnology Releases Updated Corporate Presentation
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, A...
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Translational Breast Cancer Research Consortium (TBCRC) Trial ...
Puma Biotechnology Reports Third Quarter 2022 Financial Results
LOS ANGELES--(BUSINESS WIRE)--On Nov. 3, Puma Biotechnology released its earnings results for the third quarter and first nine months of 2022.
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented updates from its Phase II SUMMIT Basket Trial of neratinib in EGFR exon 18-mutant NSCLC at EORTC/NCI/AACR 2022 Symp.
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its third quarter 2022 financial results and host a conference call on Nov. 3, 2022.
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology licensed from Takeda worldwide rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A.
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented updated findings from its Phase II SUMMIT Trial of neratinib in cervical cancer at the ESMO Congress 2022 in Paris.